drugset
Drugs / SARS-CoV2-CTLS
last change Mar 2023 re-read 3 minutes ago

SARS-CoV2-CTLS

also known as vCTLs

Cell therapy

Developed for
COVID-19
Investigated by
Children's Hospital of Philadelphia · Medical College of Wisconsin · Nationwide Children's Hospital · New York Medical College

Trials 1

today NCT04896606 · Ph 1/2
202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04896606 Sep 2021 → Dec 2026 expected COVID-19 New York Medical College Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SARS-CoV2-CTLS ClinicalTrials.gov intervention name — accepted as the source's own label NCT04896606 ↗
Known as vCTLs “SARS-CoV-2 virus-specific cytotoxic T-cell lymphocytes (vCTLs) could provide a promising modality in COVID-19 treatment.” PMID 36583990 ↗ Mar 2023
Modality Cell therapy “family donor derived SARS-CoV-2 cytotoxic t-lymphocytes” NCT04896606 ↗